Quarterly Result5 Nov 2026, 08:51 pm
HCG Reports Q2 FY27 Revenue Up 16% to ₹7,318 Mn
AI Summary
HealthCare Global Enterprises Ltd. (HCG) announced its unaudited financial results for Q2 FY27, reporting a 16% year-on-year increase in revenue to ₹7,318 million (Mn). Adjusted EBITDA grew by 17% YoY to ₹1,425 Mn, with margins improving to 19.7%. The company saw a 9% rise in patient volumes and a 7% increase in average revenue per patient (ARPP), driven by higher contributions from advanced oncology treatments and robotic surgeries. Key developments include capacity expansion with 25 new beds and the operationalization of advanced technology like MR-LINAC and robotic surgery systems. HCG also performed its first CAR-T cell therapy at HCC Ahmedabad.
Key Highlights
- Revenue increased 16% YoY to ₹7,318 Mn in Q2 FY27.
- Adjusted EBITDA grew 17% YoY to ₹1,425 Mn, with margins at 19.7%.
- Patient volumes up 9% YoY, ARPP up 7% YoY.
- Added 25 operational beds and deployed advanced medical technology.
- Performed first CAR-T cell therapy at HCC Ahmedabad.
Price Impact
More from HCG